New anticancer drugs developed by domestic companies are gradually increasing their influence in their home market. Sales of Yuhan Corp’s lung cancer treatment Leclaza are expected to exceed KRW 20 billion this year. Also, cumulative sales of Hanmi Pharmaceutical's neutropenia treatment Rolontis have exceeded KRW 10 billion just 2 two into its launch.

According to the pharmaceutical research institution IQVIA on the 22nd, sales of Leclaza increased by 30.2% YoY to reach KRW 6 billion in Q3 this year. Leclaza is a treatment for non-small cell lung cancer that was approved as the 31st novel homegrown drug in January 2021. Leclaza entered the prescription market in earnest with its reimbursement listing in J